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ABSTRACT
Background and Objectives: The plasma concentration of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is a st-
rong prognostic indicator for patients with heart failure (HF) across all stages of the condition. Several clinical trials have de-
monstrated convincingly that neurohormonal modulation on the renin angiotensin system (RAS) decreases plasma NT-pro-
BNP level and results in favorable outcomes. But there are still limited comparative data on the neuro-hormonal modulatory 
effects of two RAS inhibitors: angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Subjects and Methods: 
This study was a prospective, multi-center, randomized, open-label, controlled, and non-inferiority study involving 445 patients 
with left ventricular ejection fraction (LVEF) less than 45%. Patients were assigned to receive either valsartan (target dose of 160 
mg bid) or enalapril (target dose of 10 mg bid) for 12 months. We compared plasma NT-pro-BNP, high sensitive C-reactive pro-
tein (hs-CRP) level and echocardiographic parameters before and after treatment with valsartan or enalapril. Results: The 
NT-pro-BNP and hs-CRP levels were significantly decreased after 12 months of treatment with valsartan and enalapril. The per-
centage change was similar between both groups. LVEF improved and left ventricular internal dimensions were decreased in 
both groups, and there were no significant differences between two groups. Conclusion: Valsartan is as effective on improv-
ing plasma NT-pro-BNP level as enalapril in patients with stable chronic HF. (Korean Circ J 2011;41:61-67)
KEY WORDS:   Brain natriuretic peptide; Angiotensin-converting enzyme inhibitors; Angiotensin receptor blocker; 
 Congestive heart failure.
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Introduction
Activation of the renin-angiotensin-aldosterone system (RAS) 
promotes structural remodeling of the heart and the progress-
ion of heart failure (HF).
1)2) Angiotensin converting enzyme 
inhibitors (ACE inhibitor) act principally by blocking the for-
mation of angiotensin II.
3) In the CONSENSUS and SOLVD 
studies, enalapril significantly reduced mortality and hospitaliz-
ations for HF in patients with chronic congestive HF and re-
duced ejection fractions.
4)5) On the other hand, angiotensin re-
ceptor blocker (ARB) selectively inhibits angiotensin II type 
1 receptors. In the Val-HeFT study, valsartan improved symp-
toms of HF, left ventricular (LV) function, LV dilation and 
reduced the risk of hospitalization for HF.
6)
Neurohormone activation is characteristic of HF, and eleva-
tion of circulating N-terminal pro-brain natriuretic peptide 
(NT-pro-BNP) levels, and other neurohormones is directly 62   NT-Pro-BNP
related to mortality and morbidity.
7)8) In addition, plasma NT-
pro-BNP, secreted mainly from the ventricle, has been known 
as a useful prognostic indicator in patients with HF.
9)10) 
In the present study, we evaluated the effects of valsartan on 
plasma NT-pro-BNP levels, and cardiac remodeling in HF pa-
tients with HF, compared to patients treated with enalapril.
Subjects and Methods
Patient population
This was a multi-center, prospective, randomized, and open 
labeled design study. Patients with stable, symptomatic HF 
{New York Heart Association (NYHA) functional class II or 
III} who were on prescribed HF therapy with LV ejection frac-
tion (LVEF) <45% were enrolled from March 2004 to Febru-
ary 2006 at 10 clinical centers in the Youngnam province of 
South Korea. Patients were excluded from the study if they 
had congenital heart disease, unstable angina, recent acute 
myocardial infarction, primary hepatic failure, renal failure 
(serum creatinine >2.5 mg/dL), life-threatening ventricular 
arrhythmia or active cancer. 
Patients with stenotic valvular heart disease were also ex-
cluded. In addition, patients receiving any ARB or ACE inhi-
bitor within 1 month of study enrollment were excluded. This 
study was approved by the ethics review board at each insti-
tution. All patients provided written informed consent before 
enrollment in this study. 
Study protocol
Six hundred and two (n=602) stable HF outpatients were 
randomly assigned to two groups {Valsartan group (n=306) 
and enalapril group (n=296)}. The starting dose is 40 mg and 
5 mg for valsartan and enalapril respectively, and then in-
creased to a maximum dose of 320 mg or 20 mg, according 
to systolic blood pressure (>90 mmHg), absence of any sign 
or symptom of hypotension, and absence of serum creatitine 
>50% from baseline. If the patient satisfied one of above three 
criteria, the dosage of drugs was reduced to the previous le-
vel. All concomitant drugs to control HF were allowed, except 
ARB or ACE inhibitors.
We performed echocardiography, NT-pro-BNP and high 
sensitive C-reactive protein (hs-CRP) levels before and after 
12 months of treatment. Also, we evaluated drug tolerance, such 
as blood pressure, symptom or sign, serum creatinine and po-
tassium levels at 1, 3, 6, 9, and 12 months (Fig. 1).
Echocardiography
Following the recommendations of the American Society 
of Echocardiography,
11) LVEF was assessed using the Simpson’s 
biplane equation for calculating volumes. The LV dimension 
and left atrial diameter for assessing cardiac remodeling were 
measured in the parasternal long axis view with an M-mode 
at each center. 
Measurement of plasma N-terminal pro brain 
natriuretic peptide level
Blood samples were drawn after participants had been in 
the sitting position for 10 minutes. Specimens were placed in 
5 mL ethylenediaminetetraacetic acid tubes, immediately 
centrifuged and frozen at -80°C. Plasma NT-pro-BNP levels 
were measured by an automated system (Elecsys 2010, Roche 
Diagnostics, Indianapolis, Ind), with identical methodology 
at each center. 
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) 12.0 
(SPSS inc., Chicago, IL, USA) statistical software package was 
used for all calculations. Data are presented as mean±stand-
ard deviation for continuous variables, and as percentages for 
the categorical data. Changes in NYHA functional class were 
assessed using Wilcoxon matched pairs signed rank test. Dif-
ferences between each group were analyzed by the unpaired 
Student t-test and by paired Students t-test between before 
(baseline) and after (12 months) treatment. Linear correlation 
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Fig. 1. Study design. TTE: transthoracic echocardiography, NT-pro-BNP: N-terminal pro-brain natriuretic peptide, hs-CRP: high sensitive C-
reactive protein.
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analysis (Pearson) was used to test correlations between chan-
ges in NT-pro-BNP level and change in LV end diastolic dimen-
sion (LVEDD) and LVEF. Categorical data were analyzed us-
ing the Chi-square test. A p<0.05 was regarded as statistically 
significant. 
Results
Demographic characteristics
Among the enrolled patients, 60 patients in the valsartan 
group and 97 patients in the enalapril group withdrew from the 
study because of coughing, angioedema, dizziness, hyperka-
lemia, renal insufficiency and hypotension. Specifically, 9 pa-
tients in the valsartan group (2.9%) and 29 patients in the enala-
pril group (9.8%) were intolerant to study drugs because of 
severe coughing. Two hundreds forty six patients were includ-
ed in the analysis (mean dose 99.4 mg) in the valsartan group 
and 199 patients (mean dose 10.7 mg) in the enalapril group. 
Table 1 presents the demographic characteristics of the st-
udy population. The proportion of male in the enalapril group 
Table 1. Demographic characteristics of subjects 
Valsartan group Enalapril group p
No. of patients
Age (years)
Male (%)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Heart rate (bpm)
Hypertension (%)
Ischemic heart disease (%)
Prior myocardial infarction (%)
Prior cerebrovascular attack (%)
Diabetes (%)
Hyperlipidemia (%)
Atrial fibrillation (%)
New York Heart Association class (%)
    II
    III
Concomitant medication (%)
    Digoxin
    Beta blocker
    Calcium channel blocker
    Diuretics
    Statin
246
063.6±11.4
144 (58.5)
122.0±16.3
075.8±11.1
079.2±14.4
070 (28.5)
090 (36.6)
040 (16.3)
08 (3.3)
064 (26.0)
10 (4.1)
050 (20.3)
143 (58.1)
103 (41.9)
077 (33.3)
113 (48.9)
037 (16.1)
150 (64.9)
069 (29.9)
199
061.5±12.9
139 (69.8)
123.6±18.7
076.0±12.5
079.3±16.1
045 (22.6)
067 (33.7)
039 (19.6)
05 (2.5)
030 (15.1)
17 (8.5)
031 (15.6)
108 (54.3)
091 (45.7)
058 (32.8)
098 (55.4)
028 (15.8)
122 (68.9)
042 (23.7)
NS
0.014
NS
NS
NS
NS
NS
NS
NS
0.005
0.049
NS
NS
NS
NS
NS
NS
NS
Table 2. Biochemical and echocardiographic parameters
Valsartan group Enalapril group p
Hemoglobin (g/dL)
White blood cell (10
3/mm
3)
Blood urea nitrogen (mg/dL)
Creatinine (mg/dL)
Sodium (mg/dL)
Potassium (mg/dL)
pro-BNP (pg/mL)
hs-CRP (mg/dL)
LVEF (%)
LVESD (mm)
LVEDD (mm)
LA diameter (mm)
12.8±2.10
7.73±2.52
18.5±7.20
1.05±0.30
140.1±4.300
4.15±0.63
3,769.7±5,748.2
2.29±6.33
35.1±8.20
49.2±10.2
59.4±9.90
44.8±7.70
13.4±2.00
8.36±2.97
17.7±6.60
1.09±0.29
140.6±3.700
4.20±0.62
3,211.3±6,047.5
1.89±3.10
34.5±8.70
47.9±9.10
57.8±8.40
42.8±7.40
0.001
0.017
0.014
NS
NS
NS
NS
NS
NS
NS
NS
0.011
BNP: brain natriuretic peptide, hs-CRP: high sensitive C-reactive protein, LVEF: left ventricle ejection fraction, LVES/DD: left ventricular end 
systolic/diastolic dimension, LA: left atrium64   NT-Pro-BNP
was higher. The incidence of diabetes was higher in the val-
sartan group. The systolic and diastolic blood pressure of pa-
tients in both groups was significantly decreased after receiv-
ing study medication (valsartan: 122.0/75.8 mmHg vs. 117.3/ 
72.8 mmHg, enalapril: 123.6/76.0 mmHg vs. 120.3/74.3 mmHg, 
respectively, p<0.05). However, the percentage change in sys-
tolic and diastolic blood pressure was not different between 
both groups. 
Table 2 summarizes the baseline biochemical and echocar-
diographic parameters. The level of serum creatinine and po-
tassium were not different between both groups. The level of 
serum uric acid in the enalapril group was significantly increas-
ed, compared to the valsartan group. The LA diameter was sig-
nificantly higher in the valsartan group.
Comparison of New York Heat Association 
functional class
Fig. 2 summaries the change in the NYHA functional class 
of the patients. Patients in both groups improved after 12 mon-
ths of treatment, compared to the baseline values (p<0.001).
Comparison of echocardiographic findings
The LVEF and LVEDD in both groups were significantly 
improved 12 months after treatment initiation. However, the 
percentage changes before and after treatment was not differ-
ent in both groups (Table 3)(Fig. 3). Changes in LVEF and 
LVEDD were significantly correlated with change in NT-pro-
BNP level (Fig. 4).
Fig. 2. Changes in NYHA functional class during treatment in the two groups. NYHA: New York Heart Association.
IV
III
II
I
0
Valsartan
N
Y
H
A
Baseline                                    12 months
p<0.001
p=NS
0 0
103 9
143 107
0 130
IV
III
II
I
0
Enalapril
N
Y
H
A
Baseline                                    12 months
p<0.001
0 0
91 14
108 86
0 99
Table 3. Change of echocardiographic parameters, pro-BNP level, and hs-CRP level
Valsartan group Enalapril group p
LV ejection fraction (%)
Baseline
After 12 months
% change 
LV systolic dimension (mm)
Baseline
After 12 months
% change 
LV diastolic dimension (mm)
Baseline
After 12 months
% change
Log pro-BNP (pg/mL)
Baseline
After 12 months
% change
Log hs-CRP (mg/dL)
Baseline
After 12 months
% change
0-35.1±8.2
0-42.7±10.5*
0-26.4±40.5
0-49.2±10.2
0-45.6±10.0*
00-6.6± 17.0
0-59.4±9.9
0-56.4±8.8*
00-4.5±11.3
0-3.16±0.67
0-2.61±0.62*
0-15.3±21.0
0-0.24±0.69
0-0.56±0.54*
-105.7±589.6
-34.5±8.7
-41.9±11.1*
-32.4±49.4
-47.9±9.1
-44.7±10.2*
0-6.8±19.4
-57.8±8.4
-55.5±8.2*
0-3.1±15.1
-3.05±0.66
-2.60±0.65*
-13.6±20.1
-0.26±0.76
-0.49±0.74*
-73.3±294.9
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
*p<0.05 compared to baseline. BNP: brain natriuretic peptide, hs-CRP: high sensitive C-reactive protein, LV: left ventricleYoung Soo Lee, et al.   65
Comparison of plasma N-terminal pro-brain 
natriuretic peptide and high sensitive C-reactive 
protein levels 
Plasma NT-pro-BNP and hs-CRP levels in both groups were 
significantly reduced after 12 months of treatment. The percen-
tage change demonstrated no difference between both groups 
(Table 3)(Fig. 3). 
Discussion
The main finding of this study was that treatment of valsar-
tan significantly improved plasma NT-pro-BNP level and echo-
cardiographic parameters in patients with HF, compared to 
treatment with enalapril. 
The plasma level of NT-pro-BNP, which is secreted mainly 
from the ventricle, is a well-established powerful risk marker 
in HF. Several authors have reported that plasma NT-pro-BNP 
is a prognostic predictor of morbidity and mortality in patients 
with HF.
12-14) In addition, Maeda et al.
15) mentioned that sustain-
ed high plasma level of NT-pro-BNP after standard treatment 
was an independent risk factor for mortality in patients with 
HF. Moreover, treatment of HF guided by plasma NT-pro-BNP 
concentration has been reported to reduce cardiovascular 
events.
16) 
ACE inhibitors and ARB reduce the mortality of patients 
with HF partly by preventing LV remodeling, and plasma 
Fig. 3. Change of NT-pro-BNP and high sensitive C-reactive protein before and after treatment. NT-pro-BNP: N-terminal pro-brain natriuretic 
peptide, hs-CRP: high sensitive C-reactive protein.
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NT-pro-BNP may be a useful marker of LV remodeling.
17) 
Tsutamoto et al.
13) demonstrated that perindopril significantly 
reduced plasma NT-pro-BNP and increased LVEF in patients 
with chronic HF. In Val-HeFT, valsartan significantly reduced 
plasma NT-pro-BNP after 24 months of therapy.
18) In our st-
udy, there are consistent results on plasma NT-pro-BNP lev-
els and LV remodeling at 12 months after enalapril and val-
sartan treatment. 
Kasama et al.
19) stated that plasma NT-pro-BNP and LV vol-
ume were significantly decreased 6 months after valsartan 
treatment in patients with HF, but not after enalapril treatment. 
In contrast, the percentage change of plasma NT-pro-BNP is 
not different between both drugs in the present study. We hy-
pothesize that this difference may be due to study drug dosage. 
We tried to escalate to the target dosage of the study drugs (av-
erage dose per day 99.4 mg in valsartan vs. 10.7 mg in enala-
pril), which is higher that that used in previously reported 
studies. Plasma NT-pro-BNP concentration is reported to cor-
relate with LVEF abnormalities and LV end diastolic pressure, 
as well as with LV mass.
20) In the present study, change of plas-
ma NT-pro-BNP is significantly correlated to change in LV-
EF and LVEDD after 12 months. Because NT-pro-BNP has 
been suggested to be a marker for ventricular remodeling,
21) th-
ese findings suggest that valsartan and enalapril might have re-
versed ventricular remodeling.
The prevalence of ACE inhibitor induced cough has been 
known to be different between races.
22) Woo et al.
23) found 
that ACE inhibitor-related cough in the Hong Kong popula-
tion was significantly higher than the primarily white Auckland 
population (53% vs. 18%, respectively). Nishizawa et al.
24) re-
ported a 45% incidence of ACE inhibitor-induced cough 
among Asian women associated with 15% treatment cessa-
tion, and about a 30% incidence among Asian men with 5% 
treatment cessation. In our study, ACE inhibitor was discon-
tinued in about 10% of patients due to severe cough. Howev-
er, the prevalence of cough varied with method of data collec-
tion, analysis and symptom reporting.
25) 
There is a major limitation to this study. We did not run a core 
laboratory for assessment of NT-pro-BNP level and echocar-
diographic parameter despite this being a multi-center and 
prospective study. However, we measured the NT-pro-BNP 
level by same ELISA method and echocardiographic param-
eters by recommendation. 
In conclusion, the results suggest that RAS inhibitor can 
significantly improve plasma NT-pro-BNP levels, echocardio-
graphic parameters and clinical findings in patients with HF. 
Valsartan, the most commonly used angiotenisn receptor bloc-
ker, is as effective as enalapril in the treatment of patients with 
stable chronic HF. 
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